

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
December 17, 2020
MO HealthNet
VIA WEBEX ONLY

Committee Members Present:

Conrad Balcer, DO, Chair
Laura Kingsley, PharmD
Morgan Sperry, PharmD
Angeline Stanislaus, MD
Matthew Stinson

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Elizabeth Sissom, RN, Clinical
Management
Lisa E. Smith, Program Development
Specialist
Carmen Burton, Administrative Assistant
Dr. Timothy Kling, MD, Acting Medical
Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Jackie Hickman, Drug Rebate Unit
Supervisor
Olivia Rush, PharmD, Program Integrity
Pharmacist

Contractors in Attendance:

Jennifer Colozza, PharmD, Conduent
Megan Fast, PharmD, Conduent
Karen Powell, PharmD, Conduent
Janelle Sheen, PharmD, Conduent
Sandy Kapur, PharmD, Conduent
April Ash, PharmD, Conduent
Geri Roling, Wipro
Chelsea Pendleton, Wipro
Valerie Schmitz, Wipro

Others Attending:

Adam Kopp
Angie Schulte
Arjun M
Audrey Rattan
Brad Willie
Brenda McLaughlin
Benjamin Sloan
Brent Young
Brian Shonesy
Brian Strickland
Bryan Moore
Camille Kerr
Carrie Davis
Chelsea Leroue
Chris Guenther
Christina Brandmeyer
Christy

cvoyiatt@iyvi-inc.com

Dana Pipkin
David Large
Emily Kalmer
Erin Hohman
Frank Alvarado
Gibby Rodriguez
Gina Heinen
Gregory Mattingly
James Baumann
Jean Ritter
Jeff Mussack
Jeff Osmundson
Jessica Crews
Jessica Petrie
Joe Cirrincione
John Deason
Jonathan Leesman
Karen Floeder
Kathrin Kucharski
Kathryne Jensen
Kurt Hendrickson
Kyle
Laura Conner
Maggie Murphy
Mandy Schnelten
Mark Kaiser
Matthew Lennertz
Melissa

Michael Holmes
Michael LaFond
Michele Shirley
Phillip King
Rob Hansen
Rob Kilo
Robert Coppola

Robert Pearce
Rodney Cobb
Sean Jones
Shelley Carruba
Shelley Thompson
Stephanie Kennedy
Susie Moroney

Suzanne Morgan
Tami Sova
Terry
Terry McCurren
Tina Rhinehart
Tom Guyer
WITTEK11

<p>Welcome, Introductions and Opening Remarks</p>	<p>Conrad Balcer, Board Chair, called the meeting to order.</p> <p>Joshua Moore introduced himself and welcomed the new additions to the meeting, which included April Ash, PDL Program Manager for Conduent.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - October 2020 Eligibles by Group - July – October 2020 Expenditures by Enrollment Group - July – October 2020 Expenditures by Service - FY21 Pharmacy Spend vs July – October 2020 Total Medicaid Spend - FY21 July – December 2020 Pharmacy Expenditures - Top 4 Drug Classes per Fiscal Year - FY19 – FYTD2021 Rare Disease Expenditures - July – December 2020 Rare Disease Expenditures - FY18 – FYTD21 Tamiflu Comparison - State Fiscal Quarter 2019-2020 Rebate - Show Me Strong Recovery Plan website (https://showmestrong.mo.gov/) - COVID Vaccine Billing and Reimbursement - Early Refill Edit – still sitting at 50%
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the September 2020 meeting.</p> <p>Decision: The committee voted to accept these approved minutes with no revisions.</p>
<p>Old Business</p>	
<p>Old Business</p>	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/pdf/edit-implementation-sched-121720.pdf</p>

New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - Public comment provided by: <ul style="list-style-type: none"> o Brian Shonesy from Jazz Pharmaceuticals on Xywav <p>Decision: The committee voted to accept the presented new drug recommendations with no revisions.</p>
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o 15 Day Supply – Oral Oncology Fiscal Edit o Acetaminophen Cumulative Dose Clinical Edit o BiDil Clinical Edit o Butalbital Combinations Excessive Therapy Edit <ul style="list-style-type: none"> ▪ Discussed \$1 million savings recent changes to this edit o Butalbital Combinations without Codeine Clinical Edit o Corlanor Clinical Edit o Entresto Clinical Edit o Selzentry Clinical Edit - No public comment provided <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
15 Day Supply Fiscal Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Antipsychotics – 1st Generation (Typical) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antipsychotics – 2nd Generation (Atypical) Clinical Edit and Reference List</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose asking to clarify the meaning of the reference list and how legislation has helped direct this edit. - Reminder that MHD does reimburse pharmacists for the administration of long acting injectable agents. - Public comment provided by: <ul style="list-style-type: none"> o Erin Hohman from Janson Pharmaceuticals on Invega Sustenna; yielded time o Gibby Rodriguez from Indivior on Perseris; yielded time <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Benzodiazepines (Select Oral) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Biosimilar vs Reference Products Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>CAR T-Cell Therapy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Diabetic Supply Quantity Limit Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Duchenne Muscular Dystrophy (DMD) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">High Cost Medication Kits Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">High Risk Therapies Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Isturisa Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Morphine Milligram Equivalent Accumulation Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on current CDC recommendation of 90 MME and how the edit will not reach that threshold until a future date. - MHD is hoping for a transparent approval for those established above the MME threshold with exceptions. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Non-Oral Contraceptives Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioids – Short-Acting Combinations Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose in regards to the 7-day supply limit for cough syrups and requested clarification if this criteria was for initial fills or for all fills. Helpdesk was asked to research and report. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioids – Short-Acting Single Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Out-of-State, Non-Bordering Pharmacies Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose regarding participants on vacation in need of a prescription. This edit will have no impact on the current process for participants in this situation. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Psychotropic Medications Polypharmacy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">PrEP Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on which medications required a diagnosis code. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Spinal Muscular Atrophy (SMA) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Rob Kilo with Biogen; asked for clarification about April implementation and what changes the providers should expect with this implementation; no changes will be seen by the provider other than consolidation of the three agents into one edit. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Alzheimer’s Agents PDL Edit o Antiandrogenic Agents PDL Edit o Antiemetic 5-HT3, NK1 and Other Select Agents, Non-Injectable PDL Edit o Antiemetic, THC Derivatives PDL Edit o Anti-Parkinsonism MAO-B Inhibitor Agents PDL Edit o Hereditary Angioedema Agents PDL Edit o Opiate Emergency Reversal Agents PDL Edit - No public comment provided <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anticonvulsants, Dravet Syndrome PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antiemetic 5HT3 and NK1 Agents, Injectables PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anti-Migraine Agents, Alternative Oral Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Chelsea Leroue with Biohaven on Nurtec; yielded time <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiretrovirals, Treatment Products Reference List</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Anti-Parkinsonism Non-Ergot Dopamine Agonists PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Maggie Murphy with Teva on Ajovy o Christina Brandmeyer with Amgen on Aimovig <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Rob Hansen with Pfizer on Ibrance o Susie Moroney with Novartis Medical Affairs on Kisqali <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Fibromyalgia Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>GI Motility Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Glucagon Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Neuropathic Pain Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>NSAID Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opiate Dependence Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Gibby Rodriguez from Indivior on Sublocade

	<p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioids, Long Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Sedative Hypnotic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Skeletal Muscle Relaxants PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Somatostatic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Tramadol-Like Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - The Board discussed the recommended criteria for this product. <ul style="list-style-type: none"> o Recommended criteria changes: <ul style="list-style-type: none"> ▪ Claim is for Ingrezza: Documentation of baseline Abnormal Involuntary Movement Scale (AIMS) score ≥ 8 - Public comment provided by: <ul style="list-style-type: none"> o Maggie Murphy with Teva on Austedo o Dr. Gregory Mattingly from St. Charles MO; advocate for Open Access to VMAT2 inhibitors o John Deason with Neurocrine Biosciences on Ingrezza <p>Decision: The Board voted to accept the recommended criteria with the above revisions in blue.</p>
<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and March meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/pdf/pdl-announcement-121720.pdf</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 1st Quarter 2021 (July, August, September) - Top 25 Drugs by Paid Number 1st Quarter 2021 (July, August, September) - Call Center User Statistics November 2020 - CyberAccess Logging Information - New Drug Statistics
<p>Adjournment</p>	<p>Morgan Sperry motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via WebEx only on Thursday, March 18, 2021.</p>

Roll Call for December 17, 2020					
	<u>Board Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
September 2020 Minutes	Y	Y	MY	Y	SY
New Drug Review	Y	Y	Y	SY	MY
Clinical/Fiscal Edit – No Changes	Y	Y	Y	SY	MY
15 Day Supply FE	Y	Y	Y	SY	MY
Antipsychotics – 1st Generation (Typical) CE	Y	MY	Y	Y	SY
Antipsychotics – 2nd Generation (Atypical) CE and Reference List	Y	SY	MY	A	AB
Benzodiazepines (Select Oral) CE	Y	MY	SY	Y	Y
Biosimilar vs Reference Products FE	Y	Y	Y	SY	MY
CAR T-Cell Therapy CE	Y	Y	Y	SY	MY
Diabetic Supply Quantity Limit FE	Y	SY	MY	A	Y
Duchenne Muscular Dystrophy (DMD) CE	Y	Y	Y	MY	SY
High Cost Medication Kits FE	Y	Y	MY	SY	Y
High Risk Therapies CE	Y	SY	Y	MY	Y
Isturisa CE	Y	SY	Y	Y	MY

Morphine Milligram Equivalent Accumulation CE	Y	SY	Y	MY	Y
Neuromyelitis Optica Spectrum Disorder (NMOSD) CE	Y	Y	Y	SY	MY
Non-Oral Contraceptives FE	Y	SY	Y	MY	Y
Opioids – Short-Acting Combinations CE	Y	Y	Y	SY	MY
Opioids – Short-Acting Single Agents CE	Y	Y	MY	Y	SY
Out-of-State, Non-Bordering Pharmacies FE	Y	MY	Y	SY	Y
Psychotropic Medications Polypharmacy CE	Y	Y	Y	MY	SY
PrEP FE	Y	MY	SY	Y	Y
Spinal Muscular Atrophy (SMA) CE	Y	Y	Y	MY	SY
Transmucosal Immediate Release Fentanyl (TIRF) CE	Y	MY	SY	Y	Y
Preferred Drug List Edits With No Annual Changes	Y	Y	SY	Y	MY
Anticonvulsants, Dravet Syndrome PDL Edit	Y	MY	Y	SY	Y
Antiemetic 5HT3 and NK1 Agents, Injectables PDL Edit	Y	SY	Y	Y	MY
Anti-Migraine Agents, Alternative Oral Agents PDL Edit	Y	Y	Y	SY	MY
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit	Y	SY	Y	MY	Y
Antiretrovirals, Treatment Products Reference List	Y	MY	Y	Y	SY

Anti-Parkinsonism Non-Ergot Dopamine Agonists PDL Edit	Y	Y	MY	SY	Y
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit	Y	SY	Y	MY	Y
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit	Y	SY	Y	Y	MY
Fibromyalgia Agents PDL Edit	Y	SY	MY	Y	A
GI Motility Agents PDL Edit	Y	MY	SY	Y	A
Glucagon Agents PDL Edit	Y	SY	Y	MY	A
Neuropathic Pain Agents PDL Edit	Y	MY	SY	Y	A
NSAID Agents PDL Edit	Y	Y	MY	SY	A
Opiate Dependence Agents PDL Edit	Y	MY	Y	SY	A
Opioids, Long Acting PDL Edit	Y	MY	Y	SY	A
Sedative Hypnotic Agents PDL Edit	Y	Y	MY	SY	A
Skeletal Muscle Relaxants PDL Edit	Y	MY	Y	SY	A
Somatostatic Agents PDL Edit	Y	SY	Y	MY	A
Tramadol-Like Agents PDL Edit	Y	SY	Y	MY	A
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit	Y	SY	Y	MY	A
Motion to Close	Y	Y	MY	SY	A
Adjournment	Y	SY	Y	MY	A

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain